Item 1.01. Entry into a Material Definitive Agreement.

On October 28, 2009, Verenium Corporation ("we" or "Verenium") entered into an agreement (the "Agreement") with Syngenta Participations AG of Switzerland ("Syngenta"), whereby we gained additional exclusive rights to an array of proprietary biomolecules expressed microbially, as well as non-exclusive rights to the same biomolecules expressed through other non-plant means. Syngenta will have exclusive rights to the biomolecules expressed in plants, as well as non-exclusive rights to the same biomolecules expressed through non-plant means other than microbial. As a result of this transaction, Verenium will receive license fees, including future royalties, for a commercial enzyme candidate licensed to a third party. In addition, Verenium obtained microbial and other non-plant rights to several late-stage enzyme development candidates, including alpha amylases and glucoamylases for starch processing in biofuels production, and xylanases, beta-glucanases and thermo-stable phytases for use in the animal feed industry.

On November 3, 2009 we issued a press release announcing the completion of activities undertaken pursuant to the license and research agreement between Verenium (through its predecessor Diversa Corporation) and Syngenta dated as of December 31, 2006 (the "LRA") and the entry into the Agreement as referenced in the preceding paragraph. A copy of the press release is included with this filing as Exhibit 99.1

Item 1.02. Termination of a Material Definitive Agreement.

The Agreement referenced in Item 1.01 above had the effect of terminating the LRA effective October 28, 2009. The LRA focused on the discovery and development of a range of novel enzymes to convert pre-treated cellulosic biomass to mixed sugars, whereby Verenium (previously Diversa) engaged in the independent development and commercialization of fermentation-based enzyme combinations from its proprietary platform. Pursuant to the LRA, Syngenta had exclusive access through December 31, 2016 to enzymes from Verenium's platform to express in plants. Under the terms of the LRA, which replaced a prior agreement between the companies, Syngenta previously paid Verenium $16 million of guaranteed research funding, and was obligated to pay Verenium certain potential milestone and royalty payments aligned to product development success. No further payments will be made to Verenium by Syngenta under the LRA or the Agreement with respect to products commercialized by Syngenta.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

99.1 Press Release of Verenium Corporation dated November 3, 2009

---